Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia. - Wikidata - wikimedia - TriplyDB

Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia.

Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia.

http://www.wikidata.org/entity/Q34424570

about

Clinical development of gene therapy: results and lessons from recent successes Targeted approaches to induce immune tolerance for Pompe disease therapy Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.Extra-thymically induced T regulatory cell subsets: the optimal target for antigen-specific immunotherapy.In vivo induction of regulatory T cells for immune tolerance in hemophilia.Innovating immune tolerance induction for haemophilia.Complexity of immune responses to AAV transgene products - Example of factor IX.Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer.Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer.T cell-intrinsic TLR2 stimulation promotes IL-10 expression and suppressive activity by CD45RbHi T cells.Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A.Emerging Issues in AAV-Mediated In Vivo Gene Therapy.Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.Gene Therapy With Regulatory T Cells: A Beneficial Alliance.

P2860

Q26743393-5EB553AF-7743-41B0-937D-90ADEE08F43A Q26767363-D36C5205-0554-4DF1-9762-F57D590C861C Q33623549-AB0D78C5-67E7-4105-B0ED-33FC54072487 Q35348677-C9DE8D3F-0A4A-49E8-991E-7D7DAE682982 Q35561776-1CD376B2-A7DC-40AD-94E6-D0DD70989DC9 Q35583409-D7DB02AF-9A7F-456E-AA04-0B316BC9B4AD Q36243815-142538D6-71A1-44EA-8559-D2E5408ED10D Q36543422-8A58A2A5-54D9-453A-AB40-6D52368E91B3 Q38365254-E1D637D1-2322-40C2-8F6B-798F1F15A5E0 Q38574966-A25A081C-5B6D-4BC1-AAC1-8C8B7CCF699E Q38894155-A5CD1CAD-0309-4C6C-8E03-BD8E3FBADA78 Q39394803-4D33844C-B079-4E53-BD69-C04F428EAF79 Q39398719-7656AB2C-BA44-4B78-BAC0-BDF031DB8EB2 Q40049410-436EF616-158F-4BAB-9441-27D8398B4D09 Q40417058-163B9A36-3CCD-4BA5-8D37-7697F18A475E Q41939919-F1131441-AEFA-4701-ACBE-2D1C4269B970 Q45875675-E3FC8228-CE92-4F2A-91B1-4BF6289F2CB3 Q47554736-5C22E5FD-A47F-4517-A11C-2C3F63A378A5 Q50622853-6C8C787D-65AE-4366-B045-C0D9EABF873A Q52721830-C02DD905-C366-4015-8DF2-F0063382F1BD

P2860

Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia.

http://www.wikidata.org/entity/Q34424570

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Ex Vivo Expanded Autologous Po ...... bitor Formation in Hemophilia.

@ast

Ex Vivo Expanded Autologous Po ...... bitor Formation in Hemophilia.

@en

Ex Vivo Expanded Autologous Po ...... bitor Formation in Hemophilia.

@nl

type

label

Ex Vivo Expanded Autologous Po ...... bitor Formation in Hemophilia.

@ast

Ex Vivo Expanded Autologous Po ...... bitor Formation in Hemophilia.

@en

Ex Vivo Expanded Autologous Po ...... bitor Formation in Hemophilia.

@nl

prefLabel

Ex Vivo Expanded Autologous Po ...... bitor Formation in Hemophilia.

@ast

Ex Vivo Expanded Autologous Po ...... bitor Formation in Hemophilia.

@en

Ex Vivo Expanded Autologous Po ...... bitor Formation in Hemophilia.

@nl

P1433

Q34424570-D366DC1F-E1ED-41C6-9E3A-9F1160888704

P1476

Q34424570-61AEF23F-2ED3-4742-A0D4-D95A557FCE19

P2093

Q34424570-029AA19B-B6CE-449F-B9FE-6A521078019C

Q34424570-2D607F86-727B-456D-B741-45F26B444A6D

Q34424570-3494CCC8-D78E-4A1B-A228-DF5018308E2F

Q34424570-5B8AE4E7-F5F0-4F35-A116-9518BDC5B23C

Q34424570-84B01571-BE5D-4411-810E-83848A03A5CA

Q34424570-8F94B0A1-3E31-4E65-97E3-9F12A35008CF

Q34424570-E63335DB-DA4B-4F09-BFE3-648F9BED3FB7

Q34424570-F1C534DB-8C4C-43BD-BC77-40BCE2001657

P2860

Q34424570-00E107FF-A009-4D22-AF21-952E62535513

Q34424570-0395E2D9-02DD-4C6B-821F-1ABD3B0E8C60

Q34424570-0E1C0E6D-EE59-4EB5-B241-A045391ED939

Q34424570-175A9E7A-5719-43E3-99EE-52BF8188B0D1

Q34424570-2B59AA3A-0919-4B8D-A2D4-3084F1B77342

Q34424570-34CB8239-63BE-4A93-87F8-313842BB1FE0

Q34424570-3906DF8B-1B00-46DD-A90C-3C247F778B00

Q34424570-3D3DE9A0-D1FA-425E-AF27-FA322E1EE01F

Q34424570-49E27989-08B2-4F9A-A1FC-69641CDE6143

Q34424570-4AB0E49A-6637-4CA7-B1B0-1BA178D10750

P31

Q34424570-399B61BD-AFB2-4325-9013-128E50E7F5C0

P356

Q34424570-18F1E81F-0412-40F9-B988-BC899FCB7968

P478

Q34424570-D3A24779-6D46-4C92-9CB0-0B6DD95675D4

P50

Q34424570-B5EFD19C-DE5F-494A-8E4D-E36A5980ECB8

Q34424570-BA436C56-00B9-4F28-96ED-C02364649A15

P577

Q34424570-BEFC2B5C-E5FF-4E1C-BDD2-C72BF9C0F860

P5875

Q34424570-512B23E7-A62B-4B72-BA18-EC4F51470AFA

P698

Q34424570-7E888055-41A7-4EA0-987D-4FF631F99451

P921

Q34424570-D5E71651-CE28-457D-A845-8DE0315B2BB6

P932

Q34424570-3F3CA6E6-B4F6-4190-97EE-19B1B2E7F0F8

P356

P1433

Molecular Therapy. Methods & Clinical Development

P1476

Ex Vivo Expanded Autologous Po ...... ibitor Formation in Hemophilia

@en

P2093

Cox Terhorst

http://www.w3.org/2001/XMLSchema#string

David M Markusic

http://www.w3.org/2001/XMLSchema#string

Debalina Sarkar

http://www.w3.org/2001/XMLSchema#string

George Q Perrin

http://www.w3.org/2001/XMLSchema#string

Gongxian Liao

http://www.w3.org/2001/XMLSchema#string

Howard R Seay

http://www.w3.org/2001/XMLSchema#string

Roland W Herzog

http://www.w3.org/2001/XMLSchema#string

Todd M Brusko

http://www.w3.org/2001/XMLSchema#string

P2860

Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

Human T regulatory cell therapy: take a billion or so and call me in the morning

Regulatory T-cell therapy in transplantation: moving to the clinic

Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells

Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells

FOXP3+ regulatory T cells in the human immune system

CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.

GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells

Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation.

P31

scholarly article

P356

10.1038/MTM.2014.30

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Brad E. Hoffman

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265488842

http://www.w3.org/2001/XMLSchema#string

P698

25364772

http://www.w3.org/2001/XMLSchema#string

P921

P932

4213815

http://www.w3.org/2001/XMLSchema#string